1,721,078 research outputs found
Assessment of hepatic insulin degradation, in normoglycemic hypertensive patients, by minimal modelling of standard intravenous glucose tolerance test data
No full textRole of hepatic insulin degradation in modulating insulin delivery to peripheral circulation, in insulin-resistant hypertensive patients, is not yet fully understood. This issue was investigated here by a novel application to hypertension of a previously proposed minimal modelling of insulin and C-peptide data, using population values for insulin and C-peptide kinetics parameters. Data, from frequently sampled intravenous glucose tolerance test (FSIGTT), were analysed in ten normoglycemic, hypertensive patients (H-group), compared with eight normoglycemic, normotensive subjects (N-group), matched for age, gender and body mass index. Minimal modelling of C-peptide and insulin data provided β-cell responsiveness to glucose perturbation (first, Φ1, second, Φ2, and basal, Φb, phase), insulin secretion rate, ISR(t) and total pre-hepatic insulin secretion, TIS, as well as insulin delivery rate, IDR(t), and total insulin delivery, TID, into plasma, over 5-h test. Instantaneous normalized hepatic insulin degradation rate was computed as HIDR(t) = 1 - [IDR(t)/ISR(t)]. In our H-group, insulin sensitivity, SI, assessed by minimal model of glucose kinetics, showed a 56% reduction, which confirmed deterioration of insulin action in hypertension. This was associated with significant increase in Φ1 (105%), TIS (55%) and TID (62%). No significant alterations were observed in other characteristic parameters of secretion and hepatic degradation of insulin, such that no significant difference was observed in HIDR(t) between our H and N groups. In conclusion, an increase of first phase and total insulin secretion occurring, in our H-group, in the presence of no alteration of hepatic insulin degradation, resulted in up-regulation of total insulin delivered to plasma (TID) for insulin-resistance compensation
Roma dall’alto
No full textLa mostra, promossa in collaborazione con numerose istituzioni culturali italiane e straniere, analizza attraverso una ricca documentazione iconografica crescita e trasformazioni urbane di Roma capitale dall’unificazione nazionale ai giorni nostriThe exhibition, organized in collaboration with several Italian and foreign cultural institutions, analyzes through a rich iconographic documentation urban growth and transformations of "Roma capitale" from the national unification to the present da
HbA1c: miglior controllo con meno tempo di esercizio fisico nei diabetici over 65
No full textIntroduzione: La Whole Body Vibration (WBV) è una metodologia di allenamento capace d’incrementare alcune specifiche caratteristiche del muscolo (forza, flessibilità, sensibilità insulina). Lo scopo della ricerca è stato di osservare, su un gruppo di pazienti con diabete di tipo 2, gli effetti di un training di WBV, in alternativa all’esercizio fisico aerobico, per migliorare il parametro Emoglobina Glicata (HbA1c) con un ridotto tempo di esercizio.
Metodi: Un totale di 48 soggetti diabetici, di età compresa tra i 45 e i 78 anni, in cura presso l’Ospedale INRCA-IRCCS di Ancona - U.O.C. Diabete e Malattie Metaboliche, è stato randomizzato in due gruppi sottoposti a due differenti tipi di intervento: esercizio fisico aerobico (gruppo AG) e Whole Body Vibration (gruppo VG). I dati del parametro HbA1c sono stati raccolti all’inizio del trattamento (T0) e dopo 12 settimane, al termine del trattamento (T1).
Risultati: Nei soggetti over 65 anni di entrambi i gruppi si è evidenziata una riduzione dei valori dell’HbA1c, nel gruppo VG con significatività (p<0.05):
- gruppo AG: -1.1% (dopo un tempo di esercizio di 360’);
- gruppo VG: -6.4% (dopo un tempo di esercizio di 156’).
Conclusione: La WBV è una alternativa concreta all’esercizio aerobico; essa è particolarmente efficace in pazienti over 65 nell’incrementare la sensibilità insulinica con sedute di allenamento di breve durat
Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations
No full textWe investigated the in vitro effects of therapeutical concentrations of S 21403 (a succinic acid derivative also known as KAD 1229 and mitiglinide) on insulin and glucagon secretion during a metabolic stimulus (glucose rising from 5 to 8.33 mM) or at a stable 2.22 mM glucose using the isolated perfused rat pancreas model, and we compared them with the patterns of repaglinide and glibenclamide. Control perfusions were also performed. During 8.33 mM glucose, insulin release peaked to 339.12+/-22.87 microU/ml in controls. S 21403 enhanced insulin release (first peak 413.02+/-14.90 microU/ml; P<0.03 vs. controls, P=ns vs. repaglinide, P<0.005 vs. glibenclamide). Repaglinide increased glucose-induced first peak secretion to 409.33+/-20.05 microU/ml within the eighth minute (P<0.05 vs. controls, P<0.01 vs. glibenclamide). Glibenclamide did not affect the first phase of glucose-induced insulin release (peak of 338.41+/-29.79 microU/ml) but potentiated and delayed the second phase. No drug affected glucagon release. In conclusion, S 21403 induces a faster, more physiological pattern of insulin release than the other drugs we tested
Insulin resistance after long term pharmacological treatment of essential hypertension
No full textProceedings of the 7th European Symposium on Metabolism: Insulin Resistance, Metabolic Diseases and Diabetic Complications, Padova, Ital
Comparison of classic and two compartment minimal models for evaluation of glucose disposal indexes in hypertension
No full textDeterioration of insulin sensitivity and glucose effectiveness with age and hypertension
No full text- …
